Aclarion, Inc. has published a shareholder letter from CEO Brent Ness outlining the company's strategic priorities for 2026, with a focus on expanding adoption of its Nociscan diagnostic platform for chronic low back pain. The letter highlights key catalysts including pursuing reimbursement coverage from U.S. regional insurance providers and the anticipated initial readout from the CLARITY clinical trial in the fourth quarter of 2026. According to Ness, the company's focus remains on disciplined execution against key catalysts that can expand Nociscan adoption and strengthen the clinical and reimbursement foundation of the business.
The company, which trades on Nasdaq under symbols ACON and ACONW, emphasized that securing reimbursement coverage represents an important step toward broader payer adoption. This initiative is part of Aclarion's dual-track approach to reimbursement advancement in both the United Kingdom and the United States. The company reported strong financial positioning with a cash runway extending into 2028, which management believes supports continued execution of their strategic priorities. This financial stability comes alongside expanding commercial engagement with physicians and imaging centers, as well as growing clinical evidence supporting the Nociscan technology.
Aclarion's Nociscan platform represents a novel approach to diagnosing chronic low back pain by using magnetic resonance spectroscopy data, proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology operates as a Software-as-a-Service platform that receives MRS data from MRI machines through a cloud connection, then analyzes biomarker data using proprietary algorithms to indicate potential sources of disc pain. For patients seeking access to the technology, Aclarion maintains a site map to help locate Nociscan centers.
The company's progress in 2026 will be closely watched by both the medical community and investors, as successful reimbursement negotiations and positive clinical trial results could significantly impact the standard of care for the millions of patients suffering from chronic low back pain worldwide. The full CEO Shareholder Letter is available on the company's website.
